Short Interest in AC Immune SA (NASDAQ:ACIU) Rises By 23.9%

AC Immune SA (NASDAQ:ACIU) was the target of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 1,350,000 shares, an increase of 23.9% from the February 28th total of 1,090,000 shares. Based on an average daily volume of 182,400 shares, the days-to-cover ratio is presently 7.4 days. Currently, 2.2% of the shares of the company are sold short.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reissued a “buy” rating and issued a $16.00 price target on shares of AC Immune in a research report on Friday, March 14th.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in ACIU. Squarepoint Ops LLC purchased a new position in AC Immune during the fourth quarter worth about $118,000. Jane Street Group LLC purchased a new position in AC Immune in the 4th quarter worth approximately $66,000. Two Sigma Advisers LP bought a new position in shares of AC Immune in the 4th quarter worth $36,000. Northern Trust Corp purchased a new stake in shares of AC Immune during the 4th quarter valued at $1,088,000. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of AC Immune by 130.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 131,410 shares of the company’s stock worth $355,000 after acquiring an additional 74,358 shares during the last quarter. Institutional investors own 51.36% of the company’s stock.

AC Immune Stock Down 5.6 %

ACIU stock opened at $1.87 on Tuesday. The stock has a 50-day simple moving average of $2.47 and a two-hundred day simple moving average of $2.90. AC Immune has a twelve month low of $1.87 and a twelve month high of $4.98. The firm has a market capitalization of $187.77 million, a PE ratio of -4.07 and a beta of 1.23.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.